The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EBMT 2020 | EBV-LMP2-specific TCR for EBV associated malignancies
Wesley Huisman, MSc, Leiden University Medical Center, Leiden, The Netherlands, discusses his abstract on the development of the first functional human leukocyte antigen (HLA) 01-restricted Epstein-Barr virus latent membrane protein 2 specific (EBV-LMP2-specific) T-cell receptors (TCR) for TCR gene therapies for EBV associated malignancies. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).
